Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer
1 other identifier
observational
N/A
1 country
1
Brief Summary
The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a biomarker in cancer. Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a useful biomarker to distinguish between malignant and non-malignant causes of pleural effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to diagnose cancer or monitor the treatment progress of cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Apr 2010
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2010
CompletedFirst Submitted
Initial submission to the registry
May 24, 2010
CompletedFirst Posted
Study publicly available on registry
May 26, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2013
CompletedDecember 11, 2013
December 1, 2013
3 years
May 24, 2010
December 10, 2013
Conditions
Keywords
Study Arms (1)
Cancer patient
Interventions
Eligibility Criteria
Any cancer patient
You may qualify if:
- Any cancer patient with pleural effusion that is being drained through an indwelling chest-tube in an inpatient ward.
You may not qualify if:
- Patient with a pleural effusion who does not have proven cancer or whose pleural effusion is not known to be malignant.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National University Hospital, Singapore
Singapore, Singapore
Related Publications (2)
Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures. Eur J Cardiothorac Surg. 2008 Apr;33(4):723-7. doi: 10.1016/j.ejcts.2008.01.014. Epub 2008 Feb 7.
PMID: 18261916BACKGROUNDMazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc. 2007;(4):99-124. doi: 10.1007/2789_2008_091.
PMID: 18811055BACKGROUND
MeSH Terms
Conditions
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 24, 2010
First Posted
May 26, 2010
Study Start
April 1, 2010
Primary Completion
April 1, 2013
Study Completion
April 1, 2013
Last Updated
December 11, 2013
Record last verified: 2013-12